Rosalind Franklin University Receives $1.7 Million NIH Funding for Autism and Schizophrenia Research

Rosalind Franklin University Secures $1.7 Million NIH Funding

Rosalind Franklin University of Medicine and Science in North Chicago has proudly announced that neuroscientist Dr. Joanna Dabrowska, an established figure in the field, has secured a substantial grant totaling $1,733,330. This funding comes as a subaward from a larger five-year grant by the National Institute of Mental Health (NIMH) to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. The project aims to delve into the neural mechanisms that underpin social recognition memory, an area of vital importance for individuals facing challenges in psychiatric disorders such as schizophrenia and autism spectrum disorders (ASD).

Dr. Dabrowska, who holds positions as an associate professor in RFU's Center for Neurobiology of Stress Resilience and Psychiatric Disorders and in cellular and molecular pharmacology, is collaborating with Dr. Hala Harony-Nicolas, an associate professor at ISMMS. Their collaborative effort promises to shed light on critical aspects of neural circuits vital for social recognition.

"Our project directly addresses critical gaps in our understanding of a neural circuit that supports social recognition," Dr. Dabrowska commented. She highlighted the significance of their work: by examining how oxytocin modulates activity in the supramammillary nucleus of the hypothalamus, the research aims to uncover mechanisms that could potentially lead to new treatment options for the social deficits commonly associated with psychiatric illnesses.

The focus on oxytocin—a hormone recognized for its role in social bonding—positions this study at the intersection of neuroscience and community health. This research will explore its influence on crucial brain areas involved in recognizing and recalling social cues, offering new perspectives on longstanding questions in neuropsychiatry.

The implications of this work are particularly crucial given the prevalence of the disorders in question; schizophrenia affects roughly 2.5 million adults in the U.S., and autism spectrum disorder is currently diagnosed in approximately 1 in 36 children. Both conditions significantly hinder social interaction and overall quality of life, making advancements in therapeutic techniques imperative.

Dr. Dabrowska’s groundbreaking work in neuropsychiatry has earned her significant accolades, including recognition as an Illinois Researcher to Know by the Illinois Science and Technology Coalition. Her drive and dedication to improving the lives of those affected by social recognition impairments are evident in this substantial research endeavor.

Joseph DiMario, PhD, RFU’s Executive Vice President for Research, remarked on the potential impact of this collaboration: “Dr. Dabrowska's leadership and this partnership with Mount Sinai in New York City represent an exciting opportunity for Rosalind Franklin University and the broader scientific community. We hope this research aids in the development of new therapeutic strategies for brain disorders that present profound social deficits.”

Rosalind Franklin University of Medicine and Science, named after the pioneering scientist who played a crucial role in discovering the structure of DNA, embodies a culture of discovery and academic excellence. Its research spans a range of vital fields, from neuroscience to chronic conditions, while maintaining a commitment to enhancing medical education and healthcare practices. For more information about the university and its groundbreaking initiatives, visit rosalindfranklin.edu.